FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058233650> ?p ?o ?g. }

• W2058233650 endingPage "294" @default.
• W2058233650 startingPage "287" @default.
• W2058233650 abstract "Imexon is an aziridine-derived iminopyrrolidone which has synergy with gemcitabine in pancreatic cancer cell lines. Gemcitabine is a standard therapy for pancreatic cancer. We performed a phase I trial of imexon and gemcitabine to evaluate safety, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) in patients with advanced pancreatic cancer.Patients with untreated locally advanced or metastatic pancreatic adenocarcinoma received therapy in sequential cohorts on regimen A (n = 19; imexon 200 or 280 mg/m(2) intravenously (IV) over 30 min days 1-5, 15-19 and gemcitabine 800 or 1,000 mg/m(2) IV over 30 min on days 1,8,15 every 28 days) or regimen B (n = 86; imexon 280-1,300 mg/m(2) IV over 30-60 min days 1, 8, and 15 and gemcitabine 1,000 mg/m(2) IV over 30 min on days 1, 8, and 15 every 28 days).One hundred five patients received 340 treatment cycles (median 2, range 1-16).median age 63, 61% male, ECOG PS 0/1 50%/50%, 93% metastatic. DLT was abdominal cramping and pain, often with transient, acute diarrhea. Best response was confirmed partial response (PR) in 11.4%, 8.9% unconfirmed PR, and 48.1% with stable disease. There was a dose proportional increase in imexon AUC across the doses tested with terminal half life 69 min at the MTD and no alteration of gemcitabine pharmacokinetics.The recommended phase II dose of imexon is 875 mg/m(2) with gemcitabine 1,000 mg/m(2). DLT was acute abdominal pain and cramping. Encouraging antitumor responses support further evaluation of this combination in advanced pancreatic cancer." @default.
• W2058233650 created "2016-06-24" @default.
• W2058233650 creator A5011595369 @default.
• W2058233650 creator A5033005694 @default.
• W2058233650 creator A5033724353 @default.
• W2058233650 creator A5038787782 @default.
• W2058233650 creator A5064210978 @default.
• W2058233650 creator A5064488553 @default.
• W2058233650 creator A5065431287 @default.
• W2058233650 creator A5070130751 @default.
• W2058233650 creator A5085156317 @default.
• W2058233650 date "2009-10-24" @default.
• W2058233650 modified "2023-10-09" @default.
• W2058233650 title "A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer" @default.
• W2058233650 cites W1890647543 @default.
• W2058233650 cites W1931508686 @default.
• W2058233650 cites W2014366767 @default.
• W2058233650 cites W2018276670 @default.
• W2058233650 cites W2027390595 @default.
• W2058233650 cites W2041379917 @default.
• W2058233650 cites W2043103956 @default.
• W2058233650 cites W2053928409 @default.
• W2058233650 cites W2063670594 @default.
• W2058233650 cites W2090912466 @default.
• W2058233650 cites W2121995930 @default.
• W2058233650 cites W2123344367 @default.
• W2058233650 cites W2125942822 @default.
• W2058233650 cites W2154574630 @default.
• W2058233650 cites W2158134441 @default.
• W2058233650 cites W2269329283 @default.
• W2058233650 doi "https://doi.org/10.1007/s00280-009-1162-y" @default.
• W2058233650 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2873145" @default.
• W2058233650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19855966" @default.
• W2058233650 hasPublicationYear "2009" @default.
• W2058233650 type Work @default.
• W2058233650 sameAs 2058233650 @default.
• W2058233650 citedByCount "19" @default.
• W2058233650 countsByYear W20582336502012 @default.
• W2058233650 countsByYear W20582336502014 @default.
• W2058233650 countsByYear W20582336502016 @default.
• W2058233650 countsByYear W20582336502018 @default.
• W2058233650 countsByYear W20582336502019 @default.
• W2058233650 countsByYear W20582336502020 @default.
• W2058233650 crossrefType "journal-article" @default.
• W2058233650 hasAuthorship W2058233650A5011595369 @default.
• W2058233650 hasAuthorship W2058233650A5033005694 @default.
• W2058233650 hasAuthorship W2058233650A5033724353 @default.
• W2058233650 hasAuthorship W2058233650A5038787782 @default.
• W2058233650 hasAuthorship W2058233650A5064210978 @default.
• W2058233650 hasAuthorship W2058233650A5064488553 @default.
• W2058233650 hasAuthorship W2058233650A5065431287 @default.
• W2058233650 hasAuthorship W2058233650A5070130751 @default.
• W2058233650 hasAuthorship W2058233650A5085156317 @default.
• W2058233650 hasBestOaLocation W20582336502 @default.
• W2058233650 hasConcept C121608353 @default.
• W2058233650 hasConcept C126322002 @default.
• W2058233650 hasConcept C126894567 @default.
• W2058233650 hasConcept C143998085 @default.
• W2058233650 hasConcept C2776694085 @default.
• W2058233650 hasConcept C2776737053 @default.
• W2058233650 hasConcept C2777844706 @default.
• W2058233650 hasConcept C2778764654 @default.
• W2058233650 hasConcept C2780210213 @default.
• W2058233650 hasConcept C2780258809 @default.
• W2058233650 hasConcept C2781413609 @default.
• W2058233650 hasConcept C29730261 @default.
• W2058233650 hasConcept C31760486 @default.
• W2058233650 hasConcept C71924100 @default.
• W2058233650 hasConcept C90924648 @default.
• W2058233650 hasConceptScore W2058233650C121608353 @default.
• W2058233650 hasConceptScore W2058233650C126322002 @default.
• W2058233650 hasConceptScore W2058233650C126894567 @default.
• W2058233650 hasConceptScore W2058233650C143998085 @default.
• W2058233650 hasConceptScore W2058233650C2776694085 @default.
• W2058233650 hasConceptScore W2058233650C2776737053 @default.
• W2058233650 hasConceptScore W2058233650C2777844706 @default.
• W2058233650 hasConceptScore W2058233650C2778764654 @default.
• W2058233650 hasConceptScore W2058233650C2780210213 @default.
• W2058233650 hasConceptScore W2058233650C2780258809 @default.
• W2058233650 hasConceptScore W2058233650C2781413609 @default.
• W2058233650 hasConceptScore W2058233650C29730261 @default.
• W2058233650 hasConceptScore W2058233650C31760486 @default.
• W2058233650 hasConceptScore W2058233650C71924100 @default.
• W2058233650 hasConceptScore W2058233650C90924648 @default.
• W2058233650 hasIssue "2" @default.
• W2058233650 hasLocation W20582336501 @default.
• W2058233650 hasLocation W20582336502 @default.
• W2058233650 hasLocation W20582336503 @default.
• W2058233650 hasLocation W20582336504 @default.
• W2058233650 hasOpenAccess W2058233650 @default.
• W2058233650 hasPrimaryLocation W20582336501 @default.
• W2058233650 hasRelatedWork W1965851372 @default.
• W2058233650 hasRelatedWork W2094153719 @default.
• W2058233650 hasRelatedWork W2115579238 @default.
• W2058233650 hasRelatedWork W2126322332 @default.
• W2058233650 hasRelatedWork W2596055884 @default.
• W2058233650 hasRelatedWork W2885862304 @default.
• W2058233650 hasRelatedWork W3031244932 @default.

• next